Decreased incidence, virus transmission capacity, and severity of COVID-19 at altitude on the American continent.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
29
07
2020
accepted:
02
03
2021
entrez:
29
3
2021
pubmed:
30
3
2021
medline:
10
4
2021
Statut:
epublish
Résumé
The coronavirus disease 2019 (COVID-19) outbreak in North, Central, and South America has become the epicenter of the current pandemic. We have suggested previously that the infection rate of this virus might be lower in people living at high altitude (over 2,500 m) compared to that in the lowlands. Based on data from official sources, we performed a new epidemiological analysis of the development of the pandemic in 23 countries on the American continent as of May 23, 2020. Our results confirm our previous finding, further showing that the incidence of COVID-19 on the American continent decreases significantly starting at 1,000 m above sea level (masl). Moreover, epidemiological modeling indicates that the virus transmission rate is lower in the highlands (>1,000 masl) than in the lowlands (<1,000 masl). Finally, evaluating the differences in the recovery percentage of patients, the death-to-case ratio, and the theoretical fraction of undiagnosed cases, we found that the severity of COVID-19 is also decreased above 1,000 m. We conclude that the impact of the COVID-19 decreases significantly with altitude.
Identifiants
pubmed: 33780470
doi: 10.1371/journal.pone.0237294
pii: PONE-D-20-23585
pmc: PMC8006995
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0237294Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Respir Physiol Neurobiol. 2020 Aug;279:103448
pubmed: 32437878
Respir Physiol Neurobiol. 2020 Jun;277:103443
pubmed: 32333993
Respir Physiol Neurobiol. 2020 Aug;279:103476
pubmed: 32522574
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
Blood. 2020 Mar 26;135(13):1066-1069
pubmed: 32043119
J Travel Med. 2020 May 18;27(3):
pubmed: 32227186
Respir Physiol Neurobiol. 2020 Oct;281:103494
pubmed: 32679369
Sci Total Environ. 2020 Aug 10;729:139016
pubmed: 32361458
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
High Alt Med Biol. 2008 Summer;9(2):148-57
pubmed: 18578646
J Ethnopharmacol. 2020 Mar 25;250:112470
pubmed: 31862407
Am J Physiol. 1996 Oct;271(4 Pt 1):C1172-80
pubmed: 8897823
FASEB J. 2001 Nov;15(13):2445-53
pubmed: 11689469
Postgrad Med J. 2008 Dec;84(998):622-7; quiz 626
pubmed: 19201935
PLoS Negl Trop Dis. 2021 Jan 4;15(1):e0008958
pubmed: 33395425
Semin Fetal Neonatal Med. 2007 Aug;12(4):250-8
pubmed: 17321813
Am J Trop Med Hyg. 2020 Dec;103(6):2347-2349
pubmed: 33124543
High Alt Med Biol. 2020 Sep;21(3):217-222
pubmed: 32716669
Respir Physiol Neurobiol. 2020 Oct;281:103512
pubmed: 32739459
High Alt Med Biol. 2020 Dec;21(4):426-427
pubmed: 32803989
Wellcome Open Res. 2020 Apr 27;5:78
pubmed: 32518842
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Arch Bronconeumol (Engl Ed). 2020 Nov;56(11):760-761
pubmed: 32782091
Am J Physiol Lung Cell Mol Physiol. 2009 Oct;297(4):L631-40
pubmed: 19592460